Roth MKM lowered the firm’s price target on TFF Pharmaceuticals to $44 from $56 but keeps a Buy rating on the shares. The analyst cites the company’s updated TFF TAC and TFF VORI Phase 2 datasets, most importantly showing that in eight lung transplant patients – up from four described earlier – TFF TAC was highly effective and substantially safer than oral tacrolimus, though the firm is also updating its model and pushing out its assumed TFF VORI royalties.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TFFP:
- TFF Pharmaceuticals Shares Key Updates with Investors
- TFF Pharmaceuticals Announces Updated Data from the Tacrolimus Inhalation Powder (TFF TAC) and Voriconazole Inhalation Powder (TFF VORI) Clinical Programs
- TFF Pharmaceuticals Announces Oral Presentation of Interim Data from the Phase 2 Study of Tacrolimus Inhalation Powder (TFF TAC) for the Prevention of Lung Transplant Rejection at the 44th Annual International Society for Heart and Lung Transplantation (ISHLT) 2024 Meeting
- TFF Pharmaceuticals Announces Closing of $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
- TFF Pharmaceuticals trading resumes
